Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs Intensive Insulin in Steroid-Induced Diabetes
NCT07117240Phase 4Enrolling by invitation
- Sponsor
- Medical University of Warsaw
- Start
- Jul 2025
- Primary completion
- Feb 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of lixisenatide in steroid-induced diabetes, type 2 diabetes mellitus (T2DM), sponsored by Medical University of Warsaw. Started Jul 2025; status: enrolling by invitation.
02
Drugs
lixisenatide
03
Conditions
steroid-induced diabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07117240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117240.